EUVIMEDEUVIMED entdecken
Crossref

High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma

Yuheng Cao iD, Xue Yin, Lanrong Wu, Dehua Huang, Zheng Wang, Feng Wu, Jiang Jiang, Guangcun Chen iD, Qiangbin Wang iD

Advanced Materials · 2025

DOI: 10.1002/adma.202500623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Yuheng Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Su…. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Glaucoma, Neuroprotective Agents, Neuroprotection. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is a retinal neurodegenerative disease characterized by progressive apoptosis of retinal ganglion cells (RGCs) and irreversible visual impairment. Current therapies rarely offer direct protection for RGCs, highlighting the need for new neuroprotective approaches. Although viral delivery of brain‐derived neurotrophic factor (BDNF) has shown potential, concerns about retinal inflammation and limited applicability persist. Meanwhile, non‐viral vectors remain inefficient for in vivo ocular gene delivery. Here, a highly biocompatible nanoplatform—PBAE‐PLGA‐Oligomycin‐pBDNF nanoparticles (PPOB NPs) is reported—that co‐delivers oligomycin (an ATP inhibitor) and a BDNF plasmid to Müller cells in vivo. This nanoplatform attains an unprecedented transfection efficiency of 64.26% in Müller cells, thereby overcoming the limitations of monotherapeutic neurotrophic approaches that fail to inhibit ATP overproduction and attendant inflammatory responses. In a chronic ocular hypertension rat model, oligomycin effectively mitigated RGC damage by suppressing Müller cell hyperactivation and excessive ATP production under elevated intraocular pressure. Concurrently, it synergistically enhanced BDNF expression in Müller cells, achieving robust protection of RGCs and preservation of optic nerve function. These findings underscore the promise of PPOB NPs as a dual‐functional platform, featuring high biocompatibility and efficient gene delivery, for multifaceted therapies against glaucoma and other ocular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorGlaucomaNeuroprotective AgentsNeuroprotectionAnimalsRatsRetinal Ganglion CellsNanoparticlesEpendymoglial CellsRats, Sprague-DawleyPolylactic Acid-Polyglycolic Acid CopolymerAdenosine TriphosphateGene Transfer TechniquesHumans

Stichwörter der Autor:innen

Müller cellgene therapyglaucomaneuroprotectionretinal ganglion cell

Substanzen

Brain-Derived Neurotrophic FactorNeuroprotective AgentsPolylactic Acid-Polyglycolic Acid CopolymerAdenosine Triphosphate

Autor:innen und Institutionen

  • CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Scien…
  • School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, 21006, China.
  • School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, 230026, China.

ORCID-Profile: Yuheng Cao, Guangcun Chen, Qiangbin Wang

Förderung

  • National Key Research and Development Program
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Natural Science Foundation of Jiangsu Province
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • Science and Technology Project of Suzhou
  • Suchow Pilot Initiative for Fundamental Research
  • National Key Research and Development Program of China

Zitieren

APA

Cao, Y., Yin, X., Wu, L., Huang, D., Wang, Z., Wu, F., Jiang, J., Chen, G., & Wang, Q. (2025). High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma. Advanced Materials. https://doi.org/10.1002/adma.202500623

Vancouver

Cao Y, Yin X, Wu L, Huang D, Wang Z, Wu F, et al. High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma. Advanced Materials. 2025. doi:10.1002/adma.202500623

BibTeX
@article{Cao2025,
  author = {Cao, Yuheng and Yin, Xue and Wu, Lanrong and Huang, Dehua and Wang, Zheng and Wu, Feng and Jiang, Jiang and Chen, Guangcun and Wang, Qiangbin},
  title = {High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma},
  journal = {Advanced Materials},
  year = {2025},
  doi = {10.1002/adma.202500623}
}
Kostenlos starten →